Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Marty Makary
Biotech
Regeneron, Sanofi receive 1- to 2-month priority review vouchers
The national priority vouchers position companies including Merck KGaA, Regeneron and Sanofi to complete the review process in one to two months.
Nick Paul Taylor
Oct 17, 2025 8:30am
Fierce Pharma
Under Trump, FDA seeks to abandon expert reviews of new drugs
Sep 12, 2025 9:50am
FDA rejects another ultrarare disease prospect
Sep 8, 2025 10:59am
FDA plans real-time release of drug rejection letters
Sep 4, 2025 1:45pm
FDA proposes new approval pathway for rare diseases
Sep 3, 2025 1:20pm
Krystal discontinues melanoma study after FDA's Replimune rebuff
Aug 21, 2025 10:50am
